Sorena Kiani, EAACI 2021: Berotralstat in the Treatment of Hereditary Angioedema
touchIMMUNOLOGY joins Dr Sorena Kiani (Barts Health NHS Trust, London, UK) to discuss the efficacy and safety of berotralstat in the treatment of hereditary angioedema.
1. What are the unmet needs in the treatment of hereditary angioedema (HAE)? (00:17-01:53)
2. What is berotralstat and what is the rationale for its use in HAE? (01:53-03:17)
3. Could you give us a brief overview of the apeX-2 study and its findings? (03:17-06:04)
4. What did the recent data tell us about the long term efficacy and safety of berotralstat? (06:04-07:45)
5. What will be the next steps in the clinical development of berotralstat? (07:45-08:40)
Disclosures: Sorena Kiani has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 EAACI Annual Meeting.
Share this Video
Related Videos In Dermatological Conditions
Claudia De La Cruz, Dermatology Meeting News 2023: Effisayil 1 – a phase 2 study of spesolimab for generalized pustular psoriasis
Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prevalence, clinical presentations & impact on quality of life
Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prognosis, current treatment paradigm & pipeline therapies
The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!